The scientific understanding of preproglucagon derived peptides has provided people with
type 2 diabetes with two novel classes of glucose lowering agents, the dipeptidyl peptidase …

The Roux-en-Y gastric bypass (RYGBP) and the biliopancreatic diversion (BPD) induce long-
term control of type 2 diabetes in morbidly obese individuals. The reasons for such an effect …

Abstract Glucagon-like peptide-1 receptor (GLP-1R) activation is used in the treatment of
diabetes and obesity; however, GLP-1 induces many other physiological effects with unclear …

The proglucagon-derived peptide glucagon-like peptide-1 (GLP-1) is an intestinal signal
peptide postprandially released from the L cells of the lower gut. Exogenously administered …

Glucagon‐like peptide‐1 (GLP‐1), a gut‐derived hormone secreted in response to nutrients,
has several glucose and weight regulating actions including enhancement of glucose …

Background & Aims: Glucagon-like peptide-1 (GLP-1) regulates glucose homeostasis
through multiple mechanisms including direct actions on the endocrine pancreas and …

This review focuses on the control of appetite by food intake-regulatory peptides secreted
from the gastrointestinal tract, namely cholecystokinin, glucagon-like peptide 1, peptide YY …

Abstract Background Glucagon-like peptide-1 (GLP-1) and its based agents improve
glycemic control. Although their attenuating effect on hepatic glucose output has drawn our …

Diabetes mellitus (DM) is one of the most prevalent chronic diseases and has been a
leading cause of death in the last decades. Thus, methods to detect, prevent or delay this …

GLP‐1 is a peptide hormone from the intestinal mucosa. It is secreted in response to meal
ingestion and normally functions in the so‐called ileal brake, that is, inhibition of upper …